The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.
Kirollos Hanna, PharmD
Advertisement
Dr Kirollos Hanna, PharmD, BCOS, BCOP, FACCC, is the director of pharmacy at Minnesota Oncology.
Articles by Kirollos Hanna, PharmD
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.
Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
Advertisement
Latest Updated Articles
An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos HannaPublished: January 25th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
First-Line Zongertinib Yields Strong Responses in Patients With Advanced HER2-Mutant NSCLC
2
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
3
Physical Activity, Vaccination May Protect Against Long COVID
4
In Its 50th Year, ESMO Comes to Berlin, a City Transformed
5
